IGHG Recommendations for Anthracycline and Anthraquinone Cardiac Dysfunction Equivalence Ratios After Childhood Cancer: JACC: CardioOncology Expert Panel
Recommendations
As issued by the authors
- moderate-quality evidence; strong recommendation
Risk of cardiac dysfunction is lower with daunorubicin and higher with mitoxantrone vs doxorubicin
- low-quality evidence; moderate recommendation
Use an approximate ratio of 0.6 to convert daunorubicin to a doxorubicin-equivalent dose and a ratio of 10.5 for mitoxantrone
No recommendation for epirubicin or idarubicin due to inconclusive evidence
Original publication
IGHG Recommendations for Anthracycline and Anthraquinone Cardiac Dysfunction Equivalence Ratios After Childhood Cancer: JACC: CardioOncology Expert Panel. JACC CardioOncol. Published 20 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →